Exploration of Association Between Respiratory Vaccinations With Infection and Mortality Rates of COVID-19
Open Access
- 16 February 2021
- journal article
- research article
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 17, 1-37
Abstract
Objectives: Respiratory disease vaccines may affect COVID-19 associated infection and mortality rates due to vaccine non-specific effects against viral infections. We compared the infection and mortality rates and relation to/of COVID-19 between countries with and without universal respiratory disease vaccine policies. Methods: In this ecological study, 186 countries with COVID-19 statistics from the World Health Organization (WHO) were included. Results: The study found that countries with universal BCG (bacillus Calmette Guérin) vaccine had a significantly lower total infection and mortality rates, 0.2979 and 0.0077 vs. 3.7445, and 0.0957/1000 people and confirmed cases (P<0.001). The countries with universal Pneumococcal vaccine (PCV); including PCV1, PCV2, and PCV3 vaccines had significantly higher total mortality, 0.0111 vs. 0.0080, respectively (P=0.032). The higher income was associated with increasing total infection and mortality rates. Whereas, BCG vaccination was associated with a lower total mortality rate only (P=0.030). The high-income countries were more likely to not receive universal BCG and receive second dose of meningococcal conjugate vaccine (MCV2) and third dose of PCV3 vaccination coverage. The SARS-CoV-2 infection rates increased with increasing years of the second dose of measles-containing vaccine (P=0.026) and Pneumococcal conjugate 3rd dose (PCV3). Conclusions: This study suggests that BCG vaccination could reduce the infection caused by COVID-19 and MCV2 vaccine years increases the total infection rate. This study identified high economic characteristics and not having universal BCG coverage as the independent risk factors of mortality by the multivariate analysis.Keywords
This publication has 30 references indexed in Scilit:
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot StudyThe Journal of Infectious Diseases, 2015
- Clinical and Epidemiologic Features of Respiratory Syncytial Virus2013
- The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns”Journal of the Formosan Medical Association, 2013
- Treatment of Common and Plane Warts in Children with Topical Viable Bacillus Calmette‐GuerinPediatric Dermatology, 2012
- Progress in Respiratory Virus Vaccine DevelopmentSeminars in Respiratory and Critical Care Medicine, 2011
- Randomized Trial of BCG Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific Effects in the Neonatal Period?The Journal of Infectious Diseases, 2011
- Our Common Interest: Report of the Commission for AfricaThe Political Quarterly, 2005
- Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girlsVaccine, 2005
- Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteinsVaccine, 2000